Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

Among these are dopamine agonists and somatostatin analogs. While one would hope that the ACTH modulators would reduce tumor volume (of particular concern in patients with pituitary macroadenomas ...

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

Matching adjusted indirect comparison (MAIC) of 177Lu-DOTATATE vs. sunitinib as first-line (1L) treatment for advanced grade 2 (G2) pancreatic neuroendocrine tumors (pNETs). This is an ASCO Meeting ...

GEP-NETs constitute approximately 60.9% of primary neuroendocrine tumors. Common sites of origin include the small intestine (30.8%), rectum (26.3%), and pancreas (12.1%). Once considered rare ...

Introduction: Somatostatin (SST) is a peptide hormone primarily synthesized in the digestive and nervous systems. While its impact on the endocrine system is well-established, accumulating evidence ...

Somatostatin analogs such as octreotide and lanreotide are the cornerstone of treatment for functional neuroendocrine tumors. 1,14 These agents control symptoms by inhibiting hormone secretion and ...